Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors

被引:8
作者
Kaneko, Motoko
Ishihara, Kenji
Takahashi, Aki
Hong, JangJa
Hirasawa, Noriyasu
Zee, OkPyo
Ohuchi, Kazuo
机构
[1] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pathophysiol Biochem, Aoba Ku, Sendai, Miyagi 9808578, Japan
[2] Sungkyunkwan Univ, Grad Sch Pharm, Lab Pharmacognosy, Suwon, South Korea
[3] Sookmyung Womens Univ, Coll Pharm, Lab Pathophysiol, Seoul, South Korea
[4] Yasuda Womens Univ, Fac Pharm, Hiroshima, Japan
关键词
EoL-1; cells; eosinophils; differentiation; histone deacetylase inhibitors; FIP1L1; PDGFRA;
D O I
10.1159/000101401
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: EoL-1 cells have a FIP1L1-PDGFRA fusion gene which causes the transformation of eosinophilic precursor cells into leukemia cells. Recently, we suggested that the induction of differentiation of EoL-1 cells into eosinophils by the HDAC inhibitors apicidin and n-butyrate is due to the continuous inhibition of HDACs. However, neither apicidin nor n-butyrate inhibited the expression of FIP1L1-PDGFRA mRNA, although both these inhibitors suppressed cell proliferation. Therefore, in this study, we analyzed whether the levels of FIP1L1-PDGFR alpha protein and phosphorylated-Stat5 involved in the signaling for the proliferation of EoL-1 cells are attenuated by HDAC inhibitors. Methods: EoL-1 cells were incubated in the presence of apicidin, TSA or n-butyrate. FIP1L1-PDGFR alpha and phosphorylated-Stat5 were detected by Western blotting. Results: Treatment of EoL-1 cells with apicidin at 100 nM or n-butyrate at 500 M decreased the levels of FIP1L1-PDGFR alpha protein and phosphorylated-Stat5, while that with trichostatin A at 30 nM did not. Conclusions: The decrease in the level of FIP1L1-PDGFR alpha protein caused by apicidin and n-butyrate might be one of the mechanisms by which EoL-1 cells are induced to differentiate into eosinophils by these HDAC inhibitors. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:28 / 32
页数:5
相关论文
共 26 条
  • [1] Epigenetics and airways disease
    Adcock, IM
    Ford, P
    Ito, K
    Barnes, PJ
    [J]. RESPIRATORY RESEARCH, 2006, 7 (1)
  • [2] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
    Bali, P
    Pranpat, M
    Bradner, J
    Balasis, M
    Fiskus, W
    Guo, F
    Rocha, K
    Kumaraswamy, S
    Boyapalle, S
    Atadja, P
    Seto, E
    Bhalla, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) : 26729 - 26734
  • [3] The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    Cools, J
    Quentmeier, H
    Huntly, BJP
    Marynen, P
    Griffin, JD
    Drexler, HG
    Gilliland, DG
    [J]. BLOOD, 2004, 103 (07) : 2802 - 2805
  • [4] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    Cools, J
    DeAngelo, DJ
    Gotlib, J
    Stover, EH
    Legare, RD
    Cortes, J
    Kutok, J
    Clark, J
    Galinsky, I
    Griffin, JD
    Cross, NCP
    Tefferi, A
    Malone, J
    Alam, R
    Schrier, SL
    Schmid, J
    Rose, M
    Vandenberghe, P
    Verhoef, G
    Boogaerts, M
    Wlodarska, I
    Kantarjian, H
    Marynen, P
    Coutre, SE
    Stone, R
    Gilliland, DG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) : 1201 - 1214
  • [5] ON THE BIOLOGICAL ROLE OF HISTONE ACETYLATION
    CSORDAS, A
    [J]. BIOCHEMICAL JOURNAL, 1990, 265 (01) : 23 - 38
  • [6] Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase
    DarkinRattray, SJ
    Gurnett, AM
    Myers, RW
    Dulski, PM
    Crumley, TM
    Allocco, JJ
    Cannova, C
    Meinke, PT
    Colletti, SL
    Bednarek, MA
    Singh, SB
    Goetz, MA
    Dombrowski, AW
    Polishook, JD
    Schmatz, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) : 13143 - 13147
  • [7] Inhibition of histone deacetylase activity by butyrate
    Davie, JR
    [J]. JOURNAL OF NUTRITION, 2003, 133 (07) : 2485S - 2493S
  • [8] Histone deacetylases (HDACs): characterization of the classical HDAC family
    De Ruijter, AJM
    Van Gennip, AH
    Caron, HN
    Kemp, S
    Van Kuilenburg, ABP
    [J]. BIOCHEMICAL JOURNAL, 2003, 370 : 737 - 749
  • [9] Clinical development of histone deacetylase inhibitors as anticancer agents
    Drummond, DC
    Noble, CO
    Kirpotin, DB
    Guo, ZX
    Scott, GK
    Benz, CC
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 : 495 - 528
  • [10] Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
    Griffin, JH
    Leung, J
    Bruner, RJ
    Caligiuri, MA
    Briesewitz, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) : 7830 - 7835